Myonectin (CTRP15), compositions comprising same, and methods of use

Patent metadata

Field	Value
Publication number	US-9228005-B2
Application number	US-201314373685-A
Country	US
Kind code	B2
Filing date	Jan 24, 2013
Priority date	Jan 26, 2012
Publication date	Jan 5, 2016
Grant date	Jan 5, 2016

Abstract

Disclosed is the novel myokine known as myonectin (CTRP15), an isolated nucleic acid encoding the myonectin (CTRP15) gene, and the amino acid sequence encoding the myonectin (CTRP15) protein. Methods of isolation of the nucleic acid, protein, polypeptides and methods of making antibodies to the myonectin (CTRP15) protein are provided. The use of myonectin (CTRP15) in the modulation of lipid and/or glucose metabolism, suppressing the expression of autophagy genes, inhibiting LC3 lipidation and autophagosome-dependent p62 degradation, and activating the Akt/mTOR pathway is also provided.

First claim

The invention claimed is:

1. A method of lowering circulating serum fatty acid levels in a subject, comprising administering to the subject an effective amount of C1q tumor necrosis factor (TNF) related protein 15 (CTRP15) myonectin protein or a functional portion thereof, and a pharmaceutically acceptable carrier, wherein the functional portion is the C1q/TNF-like domain of the CTRP15 myonectin protein.

2. A method of increasing fatty acid uptake in adipocytes or hepatocytes in a subject, comprising administering to the subject an effective amount of CTRP15 myonectin protein or a functional portion thereof, and a pharmaceutically acceptable carrier, wherein the functional portion is the C1q/TNF-like domain of the CTRP15 myonectin protein.

Assignees

• Univ Johns Hopkins

Inventors

• Wong Guang William
• Seldin Marcus Michael

Classifications

• A61P3/06

  Antihyperlipidemics · CPC title

• C07K14/52 Primary

  Cytokines; Lymphokines; Interferons · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• A61K38/19 Primary

  Cytokines; Lymphokines; Interferons · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title